- Molecular profiling identifies distinct subtypes across TP53 mutant tumors
Xin Chen et al, 2022, JCI Insight CrossRef - Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy
Yizhu Xu et al, 2022, European Journal of Medicinal Chemistry CrossRef - Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer
Cathleen Nientiedt et al, 2022, Urologic Oncology: Seminars and Original Investigations CrossRef - Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities
Nicola Cosgrove et al, 2022, Nature Communications CrossRef - Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors
Curtis A. Clark et al, 2023, Journal of Immunotherapy and Precision Oncology CrossRef - BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents
Sourat Darabi et al, 2022, Medicina CrossRef - Cytocidal Antitumor Effects against Human Ovarian Cancer Cells Induced by B-Lactam Steroid Alkylators with Targeted Activity against Poly (ADP-Ribose) Polymerase (PARP) Enzymes in a Cell-Free Assay
Nikolaos Nikoleousakos et al, 2021, Biomedicines CrossRef - Low Expression of SLC7A11 Confers Drug Resistance and Worse Survival in Ovarian Cancer via Inhibition of Cell Autophagy as a Competing Endogenous RNA
Yao Ke et al, 2021, Frontiers in Oncology CrossRef - PARP inhibitor olaparib induced differential protein expression in cervical cancer cells
Jyotika Rajawat et al, 2023, Journal of Proteomics CrossRef - BRCA2 Frameshift Mutation in de novo Small-Cell Neuroendocrine Carcinoma of the Prostate: A Case Report
Keisuke Okubo et al, 2023, Case Reports in Oncology CrossRef